Comparative study of proton pump inhibitors on dexamethasone plus pylorus ligation induced ulcer model in rats
- PMID: 21188049
- PMCID: PMC3003173
- DOI: 10.4103/0250-474X.70486
Comparative study of proton pump inhibitors on dexamethasone plus pylorus ligation induced ulcer model in rats
Abstract
The present study was designed to compare ulcer protective effect of proton pump inhibitors viz. omeprazole, rabeprazole and lansoprazole against dexamethasone plus pylorus ligation induced ulcer model. Dexamethasone (5 mg/kg) was used as an ulcerogen. Dexamethasone suspended in 1% CMC in water was given orally to all the rats 15 min after the pylorus ligation. Omeprazole (20 mg/kg), rabeprazole (20 mg/kg), and lansoprazole (20 mg/kg) were administered by oral route 30 min prior to ligation was used for ulcer protective studies, gastric secretion and mucosal studies. Effects of proton pump inhibitors were determined by the evaluation of various biochemical parameters such as ulcer index, free and total acidity, gastric pH, mucin, pepsin and total proteins. Oral administration of proton pump inhibitors showed significant reduction in gastric acid secretion and ulcer protective activity against dexamethasone plus pylorus ligation induced ulcer model. The % protection of omeprazole, rabeprazole and lansoprazole was 84.04, 89.36 and 79.78, respectively. Rabeprazole significantly inhibited the acid-pepsin secretion and increased the gastric mucin secretion. The observations made in the present study suggest that rabeprazole is the most effective gastric antisecretory and ulcer healing agent as compared to omeprazole and lansoprazole.
Keywords: Dexamethasone; PPIs; mucosal offensive and defense factors.
Figures
Similar articles
-
Influence of proton pump inhibitors on dexamethasone-induced gastric mucosal damage in rats.Indian J Pharm Sci. 2011 Mar;73(2):193-8. doi: 10.4103/0250-474x.91582. Indian J Pharm Sci. 2011. PMID: 22303063 Free PMC article.
-
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. doi: 10.1016/s1086-5802(16)31036-1. J Am Pharm Assoc (Wash). 2000. PMID: 10665250 Review.
-
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.Aliment Pharmacol Ther. 2002 Oct;16(10):1811-7. doi: 10.1046/j.1365-2036.2002.01348.x. Aliment Pharmacol Ther. 2002. PMID: 12269976
-
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole.Pharmacology. 2020;105(11-12):645-651. doi: 10.1159/000506232. Epub 2020 Apr 14. Pharmacology. 2020. PMID: 32289807
-
[New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].Presse Med. 2004 Jun 19;33(11):746-54. doi: 10.1016/s0755-4982(04)98731-3. Presse Med. 2004. PMID: 15257232 Review. French.
Cited by
-
Antiulcer Activity of Indigenous Plant Operculina turpethum Linn.Evid Based Complement Alternat Med. 2013;2013:272134. doi: 10.1155/2013/272134. Epub 2013 Feb 11. Evid Based Complement Alternat Med. 2013. PMID: 23476683 Free PMC article.
-
Esomeprazole alleviates the damage to stress ulcer in rats through not only its antisecretory effect but its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways.Drug Des Devel Ther. 2019 Aug 22;13:2969-2984. doi: 10.2147/DDDT.S193641. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31686780 Free PMC article.
-
Antiulcer Effect of Honey in Nonsteroidal Anti-Inflammatory Drugs Induced Gastric Ulcer Model in Rats: A Systematic Review.Evid Based Complement Alternat Med. 2018 Jul 15;2018:7515692. doi: 10.1155/2018/7515692. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 30105063 Free PMC article. Review.
References
-
- Friedman JD, Haile PM, Siegelaaub AB, Seltzer CE. Cigarette, alcohol, coffee and peptic ulcer. N Engl J Med. 1974;290:469–73. - PubMed
-
- Manjari V, Das UN. Oxidant stress, anti-oxidants, nitric acid and essential fatty acids in peptic ulcer disease. Prostaglandins, Leukot Essent Fatty Acids. 1998;59:401–6. - PubMed
-
- Megraud F, Lamouliatte H. Helicobacter pylori and duodenal ulcer evidence suggesting causation. Dig Dis Sci. 1992;5:769–72. - PubMed
-
- Dujovne CA, Azarnoff DL. Clinical complications of corticosteroid therapy. Med Clin North Am. 1973;57:1331–42. - PubMed
LinkOut - more resources
Full Text Sources